Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

Perdiguero, Beatriz; Pérez, Patricia; Marcos-Villar, Laura; Albericio, Guillermo; Astorgano, David; Álvarez, Enrique Alarcón; Sin, Laura; Gómez, Carmen Elena; García-Arriaza, Juan; Estéban, Mariano

doi:10.1016/j.jmb.2023.168173

Cited by 8 publications

(8 citation statements)

References 249 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunization studies have tested Gag-Pol and Nef immunogens as nucleic acid vaccines (as plasmid DNA or through viral vectors) [ 69 , 70 , 71 ]. The most used viral vectors include poxviruses [e.g., vaccinia viruses (MVA or NYVAC)] [ 72 ], canarypox viruses (e.g., ALVAC) [ 10 ], and adenoviral vectors (Ad5) [ 73 ]. Some examples of Gag-based immunogens administered as vaccines are: (i) mosaic proteins, that were bioinformatically designed to cover most HIV group M variants [ 74 ]; (ii) HIV.consv constructs, that encoded for the most conserved Gag elements [ 75 ]; or (iii) HTI immunogen, that contained conserved peptides that are targeted by effective cellular immune responses [ 76 ].…”

Section: Which Immunogens Should We Use and Why?mentioning

confidence: 99%

“…There are several examples of viral vectored HIV vaccines tested in efficacy trials, as previously discussed, and viral vectors approved for use in humans (e.g., the canarypox vector ALVAC-HIV, vaccinia viruses [NYVAC, MVA, Tiantan], different adenoviruses [Ad5, Ad26, Ad35, chimpanzee adenovirus]) [ 72 , 103 , 104 , 105 ]. Their utility is indisputable, but there are some limitations that should be highlighted, such as pre-existing anti-vector responses that can interfere with the immunogenicity of the delivered antigen, as shown in the STEP study [ 11 , 106 ], or their elicitation upon vaccination.…”

Section: Nucleic Acid Vaccines and Their Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

Tarrés-Freixas,

Clotet,

Carrillo

et al. 2024

Vaccines

View full text Add to dashboard Cite

The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of developing novel immunogens and vaccination strategies that induce broadly neutralising antibodies together with potent Fc-dependent effector functions, as well as protective cross-reactive CD4+ and CD8+ T cell responses. Nucleic acid vaccines, particularly mRNA vaccines, have been one of the major groundbreaking advances in the current decade. Nucleic acid vaccines may help recalibrate the HIV vaccine field towards the use of delivery systems that allow the proper expression of immunogens as a sole antigen (i.e., membrane-bound trimeric envelope glycoproteins) or even to be displayed in a multiantigen platform that will be synthesised by the host. In this review, we will summarise how the multiple HIV vaccine strategies pursued in the last 40 years of HIV research have driven current vaccine development, which are the most relevant immunogens identified so far to induce balanced adaptive immune responses, and how they can benefit from the acceptance of nucleic acid vaccines in the market by reducing the limitations of previous delivery systems. The incorporation of nucleic acid vaccines into the current heterogeneous repertoire of vaccine platforms may represent an invaluable opportunity to reignite the fight against HIV.

show abstract

Section: Which Immunogens Should We Use and Why?mentioning

confidence: 99%

Section: Nucleic Acid Vaccines and Their Deliverymentioning

confidence: 99%

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

Tarrés-Freixas,

Clotet,

Carrillo

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…However, it is recommended that viral vectored vaccines, such as those based on measles and vaccinia viruses, be given to immunocompromised individuals or pregnant women (Ura et al 2014 , Singh et al 2019 ). However, while viral vectored vaccines are efficient at stimulating durable cellular and humoral immune reactions, they may also trigger an anti-adenovirus immune response that can decrease immunogenicity in subsequent vaccinations using the same viral vector (Zhang and Zhou 2016 , Perdiguero et al 2023 ). There may also be challenges in using the adenovirus and vaccinia viral systems for clinical purposes due to preexisting immunity toward the vectors (Table 2 ) (Cimica et al 2021 , Bifani et al 2023 ).…”

Section: Viral Vectored Vaccinesmentioning

confidence: 99%

A review on Zika vaccine development

Peng,

Yang,

et al. 2024

Pathogens and Disease

View full text Add to dashboard Cite

Zika virus (ZIKV), which belongs to the Flavivirus family, is mainly transmitted via the bite of Aedes mosquitoes. In newborns, ZIKV infection can cause severe symptoms such as microcephaly, while in adults, it can lead to Guillain‒Barré syndrome (GBS). Due to the lack of specific therapeutic methods against ZIKV, the development of a safe and effective vaccine is extremely important. Several potential ZIKV vaccines, such as live attenuated, inactivated, nucleic acid, viral vector, and recombinant subunit vaccines, have demonstrated promising outcomes in clinical trials involving human participants. Therefore, in this review, the recent developmental progress, advantages and disadvantages of these five vaccine types are examined, and practical recommendations for future development are provided.

show abstract

“…The first-generation smallpox vaccines were prepared from live, non-attenuated vaccinia viruses (VACV). Strains commonly used for producing the first-generation smallpox vaccines include the NYCBH strain (used in West Africa and North America), Lister/Elstree strain (UK), Tian Tan strain (China), and EM-63 strain (Russia and India) ( 11 ). With the rapid development of “vaccine farms” in the United States and Europe ( 12 ), extracting the virus from animals and preparing smallpox vaccines became a widely adopted and relatively safe method at the time, contributing significantly to the eventual eradication of smallpox.…”

Section: Introductionmentioning

confidence: 99%

The Current State and Progress of Mpox Vaccine Research

Wang,

Gu,

Sheng

et al. 2024

China CDC Weekly

View full text Add to dashboard Cite

On July 23, 2022, the World Health Organization (WHO) declared the monkeypox (mpox) outbreak a “Public Health Emergency of International Concern.” Since 2022, outbreaks of mpox in many countries around the world have primarily resulted in fatalities among immunocompromised individuals, such as untreated HIV/AIDS patients. Since the eradication of smallpox was declared by the WHO in 1980, the global vaccination against smallpox has been gradually discontinued. China also stopped routine smallpox vaccination in 1981. The protective effect of the smallpox vaccine has decreased over time due to aging and declining immunity in those who were vaccinated. For individuals, timely vaccination against smallpox is an effective means of protection against mpox. However, due to safety concerns with the smallpox vaccine and the limitations of current mpox vaccines, there is no vaccine that is safe, effective, and has low side effects applied in clinical settings. This article provides a comprehensive review of the development of mpox virus (MPXV) vaccines, their application in special populations, and the current state of vaccine research, considering the etiology, transmission, and prevention of the MPXV. Vaccination, as an effective method of epidemic prevention, can provide long-term immune protection and effectively reduce the severity of infection. However, as there is no licensed specific MPXV vaccine available globally, the vaccines currently used for mpox prevention are mostly smallpox vaccines. These smallpox vaccines can offer some degree of protection against mpox by activating cross-protection in the body.

show abstract

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

Cited by 8 publications

References 249 publications

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

A review on Zika vaccine development

The Current State and Progress of Mpox Vaccine Research

Contact Info

Product

Resources

About